Climb Bio ( (CLYM) ) has shared an announcement.
Climb Bio is set to host a virtual investor event to showcase its strategy for budoprutug, a promising anti-CD19 monoclonal antibody targeting B-cell mediated diseases. The event will feature insights from Dr. Frank Cortazar, who will present data from the Phase 1b trial in primary membranous nephropathy, highlighting high remission rates and B-cell depletion. The company plans further trials in systemic lupus erythematosus and immune thrombocytopenia in 2025, with a focus on advancing budoprutug’s development and leveraging its potential for immune-mediated conditions.
Learn more about CLYM stock on TipRanks’ Stock Analysis page.
